experspadmin

Guidelines Edge More Egalitarian on First-Line Biologic Choice
Rheumatology

Guidelines Edge More Egalitarian on First-Line Biologic Choice

expert roundtables
By Alan L. Epstein, MD; Daniel E. Furst, MD; Leonard H. Calabrese, DO; Stanley B. Cohen, MD
Unmet Needs in the Treatment of Rheumatoid Arthritis
Rheumatology

Unmet Needs in the Treatment of Rheumatoid Arthritis

expert roundtables
By Alan L. Epstein, MD; Daniel E. Furst, MD; Leonard H. Calabrese, DO; Stanley B. Cohen, MD
Interleukin-6 Inhibition Linked to Better Glycemic Control in Rheumatoid Arthritis
Rheumatology

Interleukin-6 Inhibition Linked to Better Glycemic Control in Rheumatoid Arthritis

clinical study insights
By Leonard H. Calabrese, DO
Examining the Need for New Treatment Biomarkers in Rheumatoid Arthritis
Rheumatology

Examining the Need for New Treatment Biomarkers in Rheumatoid Arthritis

expert roundtables
By Alan L. Epstein, MD; Daniel E. Furst, MD; Leonard H. Calabrese, DO; Stanley B. Cohen, MD
The Search for Clinically Useful Biomarkers in Rheumatoid Arthritis
Rheumatology

The Search for Clinically Useful Biomarkers in Rheumatoid Arthritis

patient care perspectives
By Alan L. Epstein, MD
Load More